More News! EMA takes down Texan biotech, American dealmaking slows

Try as we might, we can’t cover all the biotech news out there! Here’s a roundup of news that didn’t make the cut this week.

Marco Diaz Segura

  • Dealmaking in the US has slowed, disappointing optimists about biotech’s recovery

Oleksii G

  • Moderna has lifted the veil just a bit on the much-anticipated human efficacy data of its mRNA-based flu vaccine

 

Brian Lasenby

  • The EMA demolished the stock price of Texas-based XBiotech with a negative opinion of its cancer drug
  • Researchers have more details on how bacteria survive in the human immune system
  • Sandoz is off to the Supreme Court in its biosimilar battle with Amgen

 


Images from Brian Lasenby, Eric Axelson, Marco Diaz Segura, Oleksii G / shutterstock.com

Support good journalism, subscribe to Labiotech Insider

Labiotech Insider

If you liked this post and want to read more good journalism, support us by joining Labiotech Insider. Our Insider membership gives you access to exclusive content and other advantages.